Loading
Life sciences · Journal article
Nano Letters · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Pathway-targeted therapy has emerged as a promising strategy in cancer treatment, yet its efficacy relies on the accurate analysis of key signaling axes in living cells. The miR-140/FEN1 signaling axis, which is balanced in normal hepatocytes but dysregulated in hepatocellular carcinoma, represents a potential target for cancer therapy. Here, we present a DNAzyme-driven DNA nanotracker (DDN) for the orthogonal imaging of this pathway in dual channels with high sensitivity. The nanotracker is constructed by assembling DNAzyme-powered DNA walkers, which are responsive to miR-140 and FEN1, onto gold nanoparticles, enabling simultaneous visualization of upstream miRNA expression and downstream enzymatic activity in living cells. Leveraging this platform, we further revealed the differential pharmacological modulations of the miR-140/FEN1 signaling axis by simvastatin and myricetin. In summary, the DDN serves not only as a sensitive molecular imaging probe but also as a versatile tool for mechanistic studies, offering advanced opportunities for pathway-guided drug discovery and precision therapeutics.